In this video interview, Rajesh R. Tampi, MD, discusses how a new FDA-approved medication may fit into the treatment landscape for agitation associated with Alzheimer disease.
In this video interview, Rajesh R. Tampi, MD, discusses how a new FDA-approved medication may fit into the treatment landscape for agitation associated with Alzheimer disease.
In this video interview, Rajesh R. Tampi, MD, discusses how a new FDA-approved medication may fit into the treatment landscape for agitation associated with Alzheimer disease.
In this video interview, Rajesh R. Tampi, MD, discusses how a new FDA-approved medication may fit into the treatment landscape for agitation associated with Alzheimer disease.
In this video interview, Rajesh R. Tampi, MD, discusses how a new FDA-approved medication may fit into the treatment landscape for agitation associated with Alzheimer disease.
In this video interview, Rajesh R. Tampi, MD, discusses how a new FDA-approved medication may fit into the treatment landscape for agitation associated with Alzheimer disease.
In this video interview, Rajesh R. Tampi, MD, discusses how a new FDA-approved medication may fit into the treatment landscape for agitation associated with Alzheimer disease.
In this video interview, Rajesh R. Tampi, MD, discusses how a new FDA-approved medication may fit into the treatment landscape for agitation associated with Alzheimer disease.
In this video interview, Rajesh R. Tampi, MD, discusses how a new FDA-approved medication may fit into the treatment landscape for agitation associated with Alzheimer disease.
In the final installment of the Myelofibrosis Caregiver Interview Series, Fadi Haddad, MD interviews Tim F., a caregiver from Pittsburgh, PA, about the critical role caregivers play in shared...
